A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Status:
Recruiting
Trial end date:
2024-02-20
Target enrollment:
Participant gender:
Summary
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase
inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment
against first-generation TKIs. This study aims to explore the efficacy and safety of
different doses of almonertinib in the first-line and second-line treatment of brain
metastases/meningeal metastases in NSCLC patients.